太極集團(600129.SH):左氧氟沙星片獲批上市
格隆匯12月9日丨太極集團(600129.SH)公佈,近日,重慶太極實業(集團)股份有限公司控股子公司西南藥業股份有限公司(簡稱:西南藥業)收到國家藥品監督管理局關於左氧氟沙星片藥品批准通知書。
本品由重慶藥谷科技發展有限公司與西南藥業聯合研製開發。左氧氟沙星片的適應症為:用於治療成年人(≥18歲)由金黃色葡萄球菌、銅綠假單胞菌、粘質沙雷氏菌、大腸埃希菌、肺炎克雷伯桿菌、流感嗜血桿菌、肺炎鏈球菌、卡他莫拉菌、糞腸球菌或甲氧西林敏感的表皮葡萄球菌等敏感菌株所引起的下列輕、中、重度感染:1、醫院獲得性肺炎;2、社區獲得性肺炎;3、急性細菌性鼻竇炎;4、慢性支氣管炎的急性細菌性發作;5、複雜性皮膚及皮膚結構感染;6、非複雜性皮膚及皮膚軟組織感染;7、慢性細菌性前列腺炎;8、複雜性尿路感染;9、急性腎盂腎炎;10、非複雜性尿路感染;11、吸入性炭疽(暴露後)的治療。
左氧氟沙星片為《國家基本醫療保險、工傷保險和生育保險目錄(2021版)》甲類藥品。截至公吿日,經查詢國家藥品監督管理局數據庫,國內17家公司(含西南藥業)有該規格產品的生產批件。
經《Menet》數據庫統計,2021年左氧氟沙星片0.5g規格在中國城市公立醫院銷售總額約3.68億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.